Jump to Main Content

Programs

Education Spotlight Sessions

Approved, But Should We Use It? - Are the New Trial Designs Effective?

Monday, December 13, 2021, 10: 30 a.m. - 11: 15 a.m. Eastern time
Georgia World Congress Center , C208-C210, Level 2

Please view the pre-recorded presentations prior to attending the corresponding Live Q&A session. Access to the on-demand content will be available starting on December 8 and will continue through the duration of your meeting subscription. CME is available for participation in the corresponding Live Q&A.

Speakers:

Sumithra J Mandrekar, PhD
Alliance Statistics and Data Center, Mayo Clinic
Rochester, MN
Academia/Statistician Perspective

Laurie H. Sehn, MD
British Columbia Cancer Agency
Vancouver, BC, Canada
Clinician Perspective

Ann T. Farrell, MD
U.S. Food and Drug Administration
Bethesda, MD
Regulatory Perspective

Stephanie Seremetis, MD
Novo Nordisk
Plainsboro, NJ
Industry Perspective

back to top

Financial Stewardship In an Era of Hematologic Advances in Care: Whose Value? What Price?

Sunday, December 12, 2021, 4:30 p.m. - 5:15 p.m. Eastern time
Georgia World Congress Center , C208-C210, Level 2

Please view the pre-recorded presentations prior to attending the corresponding Live Q&A session. Access to the on-demand content will be available starting on December 8 and will continue through the duration of your meeting subscription. CME is available for participation in the corresponding Live Q&A.

Speakers:

Aaron Seth Kesselheim, MD
Harvard Medical School
Boston, MA
How to Assign Value to Costly Drugs?

Glenn F. Pierce, MD,PhD
Consultant
La Jolla, CA
Gene Therapy/emerging protein therapeutics  for hemophilia

Derek Robertson, MBA, JD
Maryland Sickle Cell Disease Association
Columbia, MD
Curative Options for SCD: Gene Therapy / SCT

Pedro Gascon, MD
Barcelona University
Barcelona, ESP
Biosimilar Growth Factors

John K Lin, MD
University of Pennsylvania
Philadelphia, PA
CAR-T

back to top

Genetic Testing for von Willebrand Disease

Monday, December 13, 2021, 10: 30 a.m. - 11: 15 a.m. Eastern time
Georgia World Congress Center , C211-C213, Level 2

Please view the pre-recorded presentations prior to attending the corresponding Live Q&A session. Access to the on-demand content will be available starting on December 8 and will continue through the duration of your meeting subscription. CME is available for participation in the corresponding Live Q&A.

In this session, the benefits of genetic testing including the VWD types and subtypes most suited to this analysis will be discussed. Recommendations from the recent ASH ISTH NHF WFH VWD Diagnosis Guideline on genetic testing will be incorporated.

Speakers:

Paula D. James, MD,FRCPC
Queen's University
Kingston, ON, Canada
For - Genetic Testing for vWD is Useful

Emmanuel J Favaloro, PhD
Westmead Hospital
Westmead, NSW, Australia
Against- Genetic Testing for vWD has Limited Utility

back to top

The Ups and Downs of Therapy for Children with Trisomy 21 and Acute Leukemia

Monday, December 13, 2021, 2:45 p.m. - 3:30 p.m. Eastern time
Georgia World Congress Center , C208-C210, Level 2

Please view the pre-recorded presentations prior to attending the corresponding Live Q&A session. Access to the on-demand content will be available starting on December 8 and will continue through the duration of your meeting subscription. CME is available for participation in the corresponding Live Q&A.

Speakers:

Shai Izraeli, MD
Sheba Medical Center
Petach Tikva, Israel
Understanding Down Syndrome-Associated Leukemia Biology and Cancer Predisposition

Karen R Rabin, MD,PhD
Baylor College of Medicine TX Children's Cancer Center
Houston, TX
Recent Advances in Therapy for Children with Down Syndrome-Associated B-ALL

Jason N Berman, MD
CHEO Research Institute
Ottawa, ON, Canada
Recent Advances in Therapy for Children with Down Syndrome-Associated AMKL